Enter age + axial length. In 30 seconds you have a risk score, a growth chart, and a parent-ready report — while the patient is still in the chair.
No sign up · No credit card · or enter your own patient data
Designed around chairside workflow. No training required.
Designed to support chairside decision-making without replacing clinical judgment. Outputs are clearly labelled as educational decision support.
All projection values and treatment efficacy figures are sourced directly from peer-reviewed publications.
Every number has a source. The projection engine uses peer-reviewed normative datasets and RCT-derived efficacy values — no black-box AI in the core calculation.
Composite risk score uses AL percentile (30%), growth velocity (28%), projected AL@18 (22%), parental myopia (12%), and near-work hours (8%). Weights derived from Tideman et al. 2016. The composite score is a clinical communication aid, not a validated diagnostic instrument.
Confidence intervals of ±5–10% apply. Individual outcomes vary. Population-average rates are applied; this tool does not account for individual biological variation.
Efficacy values represent change in axial elongation vs untreated control at ~2-year RCT endpoints — not final AL or cure rates. Treatment availability and regulatory approval vary by country; this site does not provide prescribing guidance. † Combination Therapy is a modeled composite (multiplicative formula, capped at 75% in-app); no single RCT validates this figure directly. ‡ Combination Therapy is shown as a range (60–75%) because no single RCT validates a precise figure. The overlap with Stellest® (67%) is intentional — at this efficacy level, combination adds marginal measurable benefit over high-efficacy monotherapy alone and the two should be considered clinically equivalent for most patients. See Methodology for the full model.
Every clinician gets full projection and comparison tools for free, forever.
Detailed clinical guidance on myopia management topics — each page cites primary literature and links directly to the tool.
View all clinical resources → · Treatment comparison → · Progression guide →
Prevalence, treatment landscape, and clinical context for the countries where myopia burden is highest.
No. MyopiaTracker is a clinical decision support tool for visualization and patient education. It does not diagnose, prescribe, or replace clinical judgment. Not FDA-cleared as a medical device.
Projections use published normative datasets (Tideman 2016, Sanz Diez 2019, He 2015) and RCT-derived treatment efficacy values. Confidence intervals of ±5–10% apply. Population-average rates; individual outcomes vary.
No. The calculator is completely free with no login required. Data stays in your browser. Cloud sync is available on the Pro plan. AI Insights work on the free plan if you provide your own Anthropic API key; Pro includes a bundled key so no separate account is needed.
In free mode, all data stays in your browser — nothing is transmitted to our servers. Pro mode uses Google Firebase (BAA-covered Firestore). A HIPAA Business Associate Agreement is available on Enterprise plans only.
Nine modalities: MiSight® 1 day, Stellest® (HALT), Ortho-K, MiyoSmart® (DIMS), Atropine 0.01%, 0.025%, 0.05%, Combination Therapy, and Outdoor/Behavioural. All efficacy values from primary RCTs.
Yes. The app is fully responsive and works on iPad and Android tablets. The free tier works completely offline — no internet required during consultations.
No signup. No card. Under 30 seconds to first result.